32 results about "Middle East respiratory syndrome" patented technology

The invention discloses a monoclonal antibody MERS-4V2 and an encoding gene and application thereof. The monoclonal antibody MERS-4V2 is an IgG antibody and comprises a heavy chain and a light chain;CDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially the 45-52nd amino acid residues, the 70-77th amino acid residues and the 116-120th amino acid residues from theN terminal in the sequence 1 in a sequence table; CDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially the 45-52nd amino acid residues, the 70-72nd amino acid residues and the 109-119th amino acid residues from the N terminal in the sequence 3 in the sequence table. The invention further discloses application of the IgG antibody in preparing medicine for inhibiting Middle East respiratory syndrome coronaviruses. The antibody has wide application prospects in developing medicine (vaccines) for treating and/or preventing the novel coronavirus MERS-CoV.

The invention discloses application of a traditional Chinese medicine composition to preparation of a drug for resisting the Middle East respiratory syndrome corona-virus (MERS-CoV). The traditional Chinese medicine composition is composed of fructus forsythia, honeysuckle, indigowoad root, rheum officinale, herba pogostemonis, rhizoma dryopteris crassirhizomae, rhodiola rosea and the like. The whole adjustment advantage of the compound traditional Chinese medicine is brought into play, the effects of removing pathogenic factors, relieving symptoms and regulating immunity are organically combined, and clinical experiment results show that the medicine provided by the invention has the effects of resisting the MERS-CoV.

The invention belongs to the technical field of biology, and relates to fused protein of an antibody and an antivirus peptide, in particular to a bispecific efficient immunotherapeutic agent, of a fully human neutralizing antibody and a high-activity MERS-CoV-inhibiting peptide, for Middle East respiratory syndrome coronaviruses (MERS-CoV), and application of the bispecific efficient immunotherapeutic agent, of the fully human neutralizing antibody and the high-activity MERS-CoV-inhibiting peptide, for the Middle East respiratory syndrome coronaviruses (MERS-CoV). The antibody-peptide bispecific immunotherapeutic agent is the fused protein of the antibody and the antivirus peptide, wherein the antibody is the high-activity fully human neutralizing antibody to the MERS-CoV, and the peptideis the high-activity MERS-CoV-inhibiting peptide. The bispecific immunotherapeutic agent has antivirus activity of the antibody and the antivirus activity of the peptide at the same time, can be usedfor further producing a potent antivirus medicine, and is especially suitable for treating disease caused by the Middle East respiratory syndrome coronaviruses (MERS-CoV).

A peptide that binds to the Si spike protein of Middle East Respiratory syndrome coronavirus or MERS-CoV and a method for inhibiting infection of a subject exposed to or having MERS-CoV by administering the peptide.

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome--Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.

The invention relates to application of a Shuanghuanglian preparation in virus infection resistance. Specifically, the invention provides an application of a chlorogenic acid compound or a pharmaceutically acceptable salt or an extract of the chlorogenic acid compound. Experiments show that the Shuanghuanglian preparation (oral liquid) and the active ingredient chlorogenic acid thereof have obvious antiviral effects on severe acute respiratory syndrome coronavirus (SARS-CoV), influenza virus (influenza virus), Middle East Respiratory Syndrome (MERS) and 2019-nCoV (new coronavirus), and prove that the Chinese patent medicine Shuanghuanglian preparation (oral liquid) can be used for treating virus infectious diseases.

Systems and methods for assessing a disease are provided. Medical imaging data of lungs of a patient is received. The lungs are segmented from the medical imaging data and abnormality regions associated with a disease are segmented from the medical imaging data. An assessment of the disease is determined based on the segmented lungs and the segmented abnormality regions. The disease may be COVID-19 (coronavirus disease 2019) or diseases, such as, e.g., SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome), or other types of viral and non-viral pneumonia.

Provided is an application of a plant as a host in expressing a vaccine of Middle East respiratory syndrome. In particular, lettuce is utilized to transiently express fusion proteins to prepare a vaccine for Middle East respiratory syndrome.

The invention relates to a traditional Chinese medicine for treating Middle East respiratory syndrome. The traditional Chinese medicine is prepared from the following traditional Chinese medicines in parts by mass: 10 parts of honeysuckle, 10 parts of fructus forsythiae, 10 parts of scutellaria baicalensis, 10 parts of schizonepeta, 10 parts of radix sileris, 5 parts of ginger, 10 parts of bupleurum falcatum, 6 parts of mint, 10 parts of ligusticum wallichii, 10 parts of tuckahoe, 10 parts of radix angelicae pubescentis, 3 parts of ephedra, 10 parts of red dates, 10 parts of adenophora stricta, 10 parts of white mulberry root-bark, and 10 parts of blackend swallowwort root.

The present invention relates to a binding molecule having neutralizing activity against Middle East Respiratory Syndrome-Coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having strong ability to bind to an S protein of MERS-CoV and neutralizing activity against MERS-CoV and thus being very useful in the prevention, treatment or diagnosis of MERS-CoV infection.

The present disclosure relates to 2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs capable of inhibiting viral infections and methods of using these compounds in the treatment of viral infections, the viral infections such as human immunodeficiency virus (HIV), human papilloma virus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), varicella, infectious mononuclear hyperplasia, parotitis, measles, rubella, herpes zoster, Ebola virus, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, and the like. Parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue fever (DENV), influenza, West Nile virus (WNV), zika virus (ZIKV), 229E, NL63, OC43, HKU1, Middle East Respiratory Syndrome Coronavivirus (MERS), severely acute respiratory Syndrome Coronavivirus (SERS), and severely acute respiratory Syndrome Coronavivirus (SERS) This abstract is intended as a scanning tool for search purposes in the particular art and is not intended as a limitation on the present invention.

The invention relates to a manufacturing method of inorganic powder, which uses soluble natural inorganic salt with an antibacterial function, and comprises the following steps: preparing materials, dissolving the materials, feeding the materials, sampling and analyzing the powder, and ageing and spray-drying a product to finally prepare the inorganic powder. The method is simple and is low in themanufacturing cost, wherein the manufactured inorganic powder has antibacterial broad spectrum and is safe to human and livestock environments, the inorganic powder can be doped into daily supplies to effectively kill various bacteria or prevent and control various viruses including atypical respiratory syndrome, Middle East respiratory syndrome, African swine fever and the like for a long time,and physical and psychological health and social stability of people can be guaranteed.

The invention discloses an MERS freeze-drying tube for detecting Middle East Respiratory Syndrome Virus, a preparation method of the MERS freeze-drying tube and a freeze-drying kit. The freeze-drying kit for detecting the Middle East Respiratory Syndrome Virus (MERS) comprises an MERS freeze-drying tube, an MERS positive control and an MERS negative control, and the MERS freeze-drying tube comprises Taq enzyme, M-MLV reverse transcriptase, an RNA enzyme inhibitor, Buffer, a primer probe mixture, dNTP, MgCl2 and a freeze-drying protective additive; the freeze-drying protective agent comprises the following components in percentage by weight: 3%-8% of trehalose, 1%-5% of mannitol, 0.1%-2% of BSA (Bovine Serum Albumin), 1%-3% of lactose and 0.05%-0.2% of tween80. The MERS positive control comprises a plasmid with a target gene. The enzyme, the buffer, the primer probe, the dNTP, the freeze-drying protective agent and the like are fully premixed to form a freeze-drying reaction system to form the freeze-drying kit, and the freeze-drying kit can be stably stored at 4-25 DEG C. Therefore, the Middle East Respiratory Syndrome Coronavirus in the sample can be rapidly, efficiently and qualitatively detected, the reaction is totally closed, and only one sample adding operation is performed; the invention relates to a freeze-drying kit which can be stored and transported at normal temperature.